Bioconvergence & future human health, with Shai Melcer
Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.
Newsletters and Deep Dive digital magazine
Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.
Bayer has looked internally for its chief medical officer, appointing Christoph Koenen to the post alongside his current clinical development role.
Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new drugs.
Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.
AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.
Editor's Picks
Newsletters and Deep Dive
digital magazine